Skip to content

Evaluation of clinical efficacy of COVID-19 vaccination in patients with hematological diseases.

Evaluation of clinical efficacy of COVID-19 vaccination in patients with hematological diseases. - Evaluation of clinical efficacy of COVID-19 vaccination in patients with hematological diseases.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000045267
Enrollment
550
Registered
2021-08-26
Start date
2021-08-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematological diseases

Interventions

None listed

Sponsors

Blood Disorders Center, Aiiku Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with hematological diseases, who are treated or followed at Aiiku Hospital.

Exclusion criteria

Exclusion criteria: Patients who are judged to be ineligible for the study.

Design outcomes

Primary

MeasureTime frame
Evaluation of SARS-COV2 spike protein seropositivity at 2w, 3m, 6m, 9m and 12m after vaccination.

Countries

Japan

Contacts

Public ContactTakeshi Kondo

Aiiku Hospital Blood Disorders Center

kondo@aiiku-hp.or.jp+81-11-563-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026